Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Net Cash Flow (2018 - 2025)

Serina Therapeutics' Net Cash Flow history spans 8 years, with the latest figure at $2.6 million for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 191.39% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $5.4 million, up 225.31%, while the annual FY2024 figure was -$3.9 million, 155.17% down from the prior year.
  • Net Cash Flow for Q3 2025 was $2.6 million at Serina Therapeutics, up from $1.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $8.8 million in Q2 2023 and bottomed at -$2.9 million in Q3 2024.
  • The 5-year median for Net Cash Flow is $66000.0 (2021), against an average of $439842.1.
  • The largest annual shift saw Net Cash Flow plummeted 457.58% in 2022 before it skyrocketed 3368.5% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$147000.0 in 2021, then surged by 221.77% to $179000.0 in 2022, then crashed by 78.77% to $38000.0 in 2023, then soared by 1147.37% to $474000.0 in 2024, then surged by 455.06% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Net Cash Flow are $2.6 million (Q3 2025), $1.7 million (Q2 2025), and $595000.0 (Q1 2025).